11 results on '"Panwankar, R."'
Number of results to display per page
Search Results
2. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic overview of systematic reviews
- Author
-
Nurmatov, U. Dhami, S. Arasi, S. Roberts, G. Pfaar, O. Muraro, A. Ansotegui, I.J. Calderon, M. Cingi, C. Durham, S. Van Wijk, R.G. Halken, S. Hamelmann, E. Hellings, P. Jacobsen, L. Knol, E. Larenas-Linnemann, D. Lin, S.Y. Maggina, V. Oude-Elberink, H. Pajno, G. Panwankar, R. Pastorello, E. Pitsios, C. Rotiroti, G. Timmermans, F. Tsilochristou, O. Varga, E.-M. Wilkinson, J. Williams, A. Worm, M. Zhang, L. Sheikh, A.
- Abstract
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis (ARC). To inform the development of recommendations, we sought to critically assess the systematic review evidence on the effectiveness, safety and cost-effectiveness of AIT for ARC. Methods: We undertook a systematic overview, which involved searching nine international biomedical databases from inception to October 31, 2015. Studies were independently screened by two reviewers against pre-defined eligibility criteria and critically appraised using the Critical Appraisal Skills Programme (CASP) Systematic Review Checklist for systematic reviews. Data were descriptively synthesized. Results: Our searches yielded a total of 5932 potentially eligible studies, from which 17 systematic reviews met our inclusion criteria. Eight of these were judged to be of high, five moderate and three low quality. These reviews suggested that, in carefully selected patients, subcutaneous (SCIT) and sublingual (SLIT) immunotherapy resulted in significant reductions in symptom scores and medication requirements. Serious adverse outcomes were rare for both SCIT and SLIT. Two systematic reviews reported some evidence of potential cost savings associated with use of SCIT and SLIT. Conclusions: We found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients, reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and protocols studied. There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT. We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated into the published systematic reviews. © 2017 The Author(s).
- Published
- 2017
3. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis
- Author
-
Dhami, S. Nurmatov, U. Arasi, S. Khan, T. Asaria, M. Zaman, H. Agarwal, A. Netuveli, G. Roberts, G. Pfaar, O. Muraro, A. Ansotegui, I.J. Calderon, M. Cingi, C. Durham, S. van Wijk, R.G. Halken, S. Hamelmann, E. Hellings, P. Jacobsen, L. Knol, E. Larenas-Linnemann, D. Lin, S. Maggina, P. Mösges, R. Oude Elberink, H. Pajno, G. Panwankar, R. Pastorello, E. Penagos, M. Pitsios, C. Rotiroti, G. Timmermans, F. Tsilochristou, O. Varga, E.-M. Schmidt-Weber, C. Wilkinson, J. Williams, A. Worm, M. Zhang, L. Sheikh, A.
- Abstract
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis. To inform the development of clinical recommendations, we undertook a systematic review to assess the effectiveness, cost-effectiveness, and safety of AIT in the management of allergic rhinoconjunctivitis. Methods: We searched nine international biomedical databases for published, in-progress, and unpublished evidence. Studies were independently screened by two reviewers against predefined eligibility criteria and critically appraised using established instruments. Our primary outcomes of interest were symptom, medication, and combined symptom and medication scores. Secondary outcomes of interest included cost-effectiveness and safety. Data were descriptively summarized and then quantitatively synthesized using random-effects meta-analyses. Results: We identified 5960 studies of which 160 studies satisfied our eligibility criteria. There was a substantial body of evidence demonstrating significant reductions in standardized mean differences (SMD) of symptom (SMD −0.53, 95% CI −0.63, −0.42), medication (SMD −0.37, 95% CI −0.49, −0.26), and combined symptom and medication (SMD −0.49, 95% CI −0.69, −0.30) scores while on treatment that were robust to prespecified sensitivity analyses. There was in comparison a more modest body of evidence on effectiveness post-discontinuation of AIT, suggesting a benefit in relation to symptom scores. Conclusions: AIT is effective in improving symptom, medication, and combined symptom and medication scores in patients with allergic rhinoconjunctivitis while on treatment, and there is some evidence suggesting that these benefits are maintained in relation to symptom scores after discontinuation of therapy. © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
- Published
- 2017
4. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic overview of systematic reviews
- Author
-
Nurmatov, U. (Ulugbek), Dhami, S. (Sangeeta), Arasi, S. (Stefania), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Durham, S. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Larenas-Linnemann, D. (Désirée), Lin, S.Y. (Sandra Y.), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), Sheikh, A. (Aziz), Nurmatov, U. (Ulugbek), Dhami, S. (Sangeeta), Arasi, S. (Stefania), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Durham, S. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Larenas-Linnemann, D. (Désirée), Lin, S.Y. (Sandra Y.), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), and Sheikh, A. (Aziz)
- Published
- 2017
- Full Text
- View/download PDF
5. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis
- Author
-
CTI, MS Dermatologie/Allergologie, Infection & Immunity, CDL Celdiagnostiek, Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., Sheikh, A., CTI, MS Dermatologie/Allergologie, Infection & Immunity, CDL Celdiagnostiek, Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., and Sheikh, A.
- Published
- 2017
6. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews
- Author
-
Nurmatov, U, Dhami, S, Arasi, S, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Larenas-Linnemann, D, Lin, SY, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, van den Worm, M (M.), Zhang, Lei, Sheikh, A (Aziz), Nurmatov, U, Dhami, S, Arasi, S, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Larenas-Linnemann, D, Lin, SY, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, van den Worm, M (M.), Zhang, Lei, and Sheikh, A (Aziz)
- Published
- 2017
7. Allergen immunotherapy for allergic rhinoconjunctivitis: Protocol for a systematic review
- Author
-
Dhami, S. (Sangeeta), Nurmatov, U. (Ulugbek), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Demoly, P., Durham, S.R. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Linnemann, D.L. (D. Larenas), Lin, S. (Sandra), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), Sheikh, A. (Aziz), Dhami, S. (Sangeeta), Nurmatov, U. (Ulugbek), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Demoly, P., Durham, S.R. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Linnemann, D.L. (D. Larenas), Lin, S. (Sandra), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), and Sheikh, A. (Aziz)
- Abstract
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Allergic Rhinoconjunctivitis. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic rhinoconjunctivitis. Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently scree
- Published
- 2016
- Full Text
- View/download PDF
8. Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review
- Author
-
Dhami, S, Nurmatov, U, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Demoly, P, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Linnemann, DL, Lin, S, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, Worm, M, Zhang, L, Sheikh, A (Aziz), Dhami, S, Nurmatov, U, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Demoly, P, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Linnemann, DL, Lin, S, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, Worm, M, Zhang, L, and Sheikh, A (Aziz)
- Published
- 2016
9. Erratum to: Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review.
- Author
-
Dhami S, Nurmatov U, Roberts G, Pfaar O, Muraro A, Ansotegui IJ, Calderon M, Cingi C, Demoly P, Durham S, van Wijk RG, Halken S, Hamelmann E, Hellings P, Jacobsen L, Knol E, Linnemann DL, Lin S, Maggina V, Oude-Elberink H, Pajno G, Panwankar R, Pastorello E, Pitsios C, Rotiroti G, Timmermans F, Tsilochristou O, Varga EM, Wilkinson J, Williams A, Worm M, Zhang L, and Sheikh A
- Abstract
[This corrects the article DOI: 10.1186/s13601-016-0099-6.].
- Published
- 2017
- Full Text
- View/download PDF
10. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews.
- Author
-
Nurmatov U, Dhami S, Arasi S, Roberts G, Pfaar O, Muraro A, Ansotegui IJ, Calderon M, Cingi C, Durham S, van Wijk RG, Halken S, Hamelmann E, Hellings P, Jacobsen L, Knol E, Larenas-Linnemann D, Lin SY, Maggina V, Oude-Elberink H, Pajno G, Panwankar R, Pastorello E, Pitsios C, Rotiroti G, Timmermans F, Tsilochristou O, Varga EM, Wilkinson J, Williams A, Worm M, Zhang L, and Sheikh A
- Abstract
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis (ARC). To inform the development of recommendations, we sought to critically assess the systematic review evidence on the effectiveness, safety and cost-effectiveness of AIT for ARC., Methods: We undertook a systematic overview, which involved searching nine international biomedical databases from inception to October 31, 2015. Studies were independently screened by two reviewers against pre-defined eligibility criteria and critically appraised using the Critical Appraisal Skills Programme (CASP) Systematic Review Checklist for systematic reviews. Data were descriptively synthesized., Results: Our searches yielded a total of 5932 potentially eligible studies, from which 17 systematic reviews met our inclusion criteria. Eight of these were judged to be of high, five moderate and three low quality. These reviews suggested that, in carefully selected patients, subcutaneous (SCIT) and sublingual (SLIT) immunotherapy resulted in significant reductions in symptom scores and medication requirements. Serious adverse outcomes were rare for both SCIT and SLIT. Two systematic reviews reported some evidence of potential cost savings associated with use of SCIT and SLIT., Conclusions: We found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients, reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and protocols studied. There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT. We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated into the published systematic reviews.
- Published
- 2017
- Full Text
- View/download PDF
11. Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review.
- Author
-
Dhami S, Nurmatov U, Roberts G, Pfaar O, Muraro A, Ansotegui IJ, Calderon M, Cingi C, Demoly P, Durham S, van Wijk RG, Halken S, Hamelmann E, Hellings P, Jacobsen L, Knol E, Larenas-Linnemann D, Lin S, Maggina V, Oude-Elberink H, Pajno G, Panwankar R, Pastorello E, Pitsios C, Rotiroti G, Timmermans F, Tsilochristou O, Varga EM, Wilkinson J, Williams A, Worm M, Zhang L, and Sheikh A
- Abstract
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Allergic Rhinoconjunctivitis. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic rhinoconjunctivitis., Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised., Conclusion: The findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.